 |
Diseases |  |
Trials |
|
Trials |  |
News |  |
- ||||||||| paridiprubart (EB07) / Edesa Biotech, Light Chain Biosci
Trial suspension: A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of EB05 + SOC Vs. Placebo + SOC in Adult Hospitalized Patients with COVID-19 (clinicaltrials.gov) - Nov 13, 2024
P2/3, N=644, Suspended, Sponsor: Edesa Biotech Inc.
Recruiting --> Suspended
- ||||| paridiprubart (EB07) / Edesa Biotech, Light Chain Biosci
Phase classification, Enrollment change, Trial completion date, Trial primary completion date: A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of EB05 + SOC Vs. Placebo + SOC in Adult Hospitalized Patients with COVID-19 (clinicaltrials.gov) - Aug 1, 2023
P2/3, N=644, Recruiting, Sponsor: Edesa Biotech Inc.
Recruiting --> Suspended Phase classification: P2 --> P2/3 | N=396 --> 644 | Trial completion date: Apr 2021 --> Dec 2024 | Trial primary completion date: Apr 2021 --> Dec 2024
- ||| EB05 / Edesa Biotech, Light Chain Biosci
P3 data: @EdesaBiotech starting Phase 3 EB05 trials for Severe COVID any day now (Twitter) - Apr 5, 2022
- |||| paridiprubart (EB07) / Edesa Biotech, Light Chain Biosci
Enrollment open, Phase classification, Enrollment change: A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of EB05 + SOC Vs. Placebo + SOC in Adult Hospitalized Patients with COVID-19 (clinicaltrials.gov) - Jan 11, 2021
P2, N=396, Recruiting, Sponsor: Edesa Biotech Inc.
Phase classification: P2 --> P2/3 | N=396 --> 644 | Trial completion date: Apr 2021 --> Dec 2024 | Trial primary completion date: Apr 2021 --> Dec 2024 Not yet recruiting --> Recruiting | Phase classification: P2/3 --> P2 | N=865 --> 396
- ||||| paridiprubart (EB07) / Edesa Biotech, Light Chain Biosci
Phase classification, Enrollment change, Trial completion date, Trial primary completion date: A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of EB05 + SOC Vs. Placebo + SOC in Adult Hospitalized Patients with COVID-19 (clinicaltrials.gov) - Jun 20, 2020
P2/3, N=865, Not yet recruiting, Sponsor: Edesa Biotech Inc.
Not yet recruiting --> Recruiting | Phase classification: P2/3 --> P2 | N=865 --> 396 Phase classification: P2 --> P2/3 | N=510 --> 865 | Trial completion date: Oct 2020 --> Apr 2021 | Trial primary completion date: Sep 2020 --> Feb 2021
- |||||||||| paridiprubart (EB07) / Edesa Biotech, Light Chain Biosci
New P2 trial, New P2/3 trial: A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of EB05 + SOC Vs. Placebo + SOC in Adult Hospitalized Patients with COVID-19 (clinicaltrials.gov) - May 26, 2020
P2, N=510, Not yet recruiting, Sponsor: Edesa Biotech Inc.
- | paridiprubart (EB07) / Edesa Biotech, Light Chain Biosci
Trial completion, Trial completion date, Trial primary completion date: Study of an Anti-TLR4 mAb in Rheumatoid Arthritis (clinicaltrials.gov) - Aug 10, 2018
P2, N=90, Completed, Sponsor: NovImmune SA
Phase classification: P2 --> P2/3 | N=510 --> 865 | Trial completion date: Oct 2020 --> Apr 2021 | Trial primary completion date: Sep 2020 --> Feb 2021 Recruiting --> Completed | Trial completion date: Oct 2018 --> Jun 2018 | Trial primary completion date: Oct 2018 --> Jun 2018
- ||||| paridiprubart (EB07) / Edesa Biotech, Light Chain Biosci
New P2 trial: Study of an Anti-TLR4 mAb in Rheumatoid Arthritis (clinicaltrials.gov) - Aug 25, 2017
P2, N=81, Recruiting, Sponsor: NovImmune SA
- ||| paridiprubart (EB07) / Edesa Biotech, Light Chain Biosci
Trial completion, Trial primary completion date: NI-0101-01: First in Human Study of an Anti-Toll-like Receptor 4 (TLR4) Monoclonal Antibody (NI-0101) in Adult Healthy Volunteers (clinicaltrials.gov) - Oct 24, 2014
P1, N=80, Completed, Sponsor: NovImmune SA
Recruiting --> Completed | Trial completion date: Oct 2018 --> Jun 2018 | Trial primary completion date: Oct 2018 --> Jun 2018 Recruiting --> Completed | Trial primary completion date: Dec 2013 --> Mar 2014
- ||| paridiprubart (EB07) / Edesa Biotech, Light Chain Biosci
New P1 trial: NI-0101-01: First in Human Study of an Anti-Toll-like Receptor 4 (TLR4) Monoclonal Antibody (NI-0101) in Adult Healthy Volunteers (clinicaltrials.gov) - Mar 7, 2013
P1, N=80, Recruiting, Sponsor: NovImmune SA